+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atherosclerosis Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Niacin), Administration Route (Injectable, Oral), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030- Product Image
Atherosclerosis Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Niacin), Administration Route (Injectable, Oral), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030- Product Image
Sale

Atherosclerosis Drugs Market by Drug Class (Bile Acid Sequestrants, Fibrates, Niacin), Administration Route (Injectable, Oral), Distribution Channel, Dosage Form, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967871
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The atherosclerosis drugs market is experiencing robust transformation as healthcare systems adapt to new therapies, regulatory shifts, and evolving patient expectations. Stakeholders are repositioning resources to address rising risk factors, regulatory complexities, and advances in drug development aimed at improving cardiovascular outcomes.

Market Snapshot: Atherosclerosis Drugs Market Growth and Outlook

The atherosclerosis drugs market grew from USD 23.82 billion in 2024 to USD 25.25 billion in 2025. It is projected to continue expanding at a CAGR of 5.71%, reaching USD 33.25 billion by 2030. This upward trajectory reflects significant investments from both established pharmaceutical leaders and emerging biotech firms. The market’s momentum is driven by a heightened focus on metabolic and cardiovascular disorders, aging demographics, and rapid innovation in lipid-lowering drug classes and therapies. Industry players are targeting greater efficacy and improved safety to address persistent clinical needs and shifting regulatory demands.

Scope & Segmentation

This report delivers a comprehensive analysis of the atherosclerosis drug market, including advanced and foundational pharmacotherapies, supply chain dynamics, technology integrations, and competitive positioning. Segmentation spans multiple dimensions:

  • Drug Classes: Bile acid sequestrants (cholestyramine, colesevelam, colestipol); fibrates (fenofibrate, gemfibrozil); niacin (extended release, immediate release); omega-3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid); PCSK9 inhibitors (alirocumab, evolocumab); statins (atorvastatin, pravastatin, rosuvastatin, simvastatin).
  • Administration Routes: Injectables (intravenous); orals (capsule, tablet).
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • Dosage Forms: Capsule, injection, tablet.
  • End User Settings: Clinic, home care, hospital.
  • Geographic Regions: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina); Europe, Middle East & Africa (including the United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Industry Participants: Amgen Inc., Novartis AG, Pfizer Inc., Sanofi S.A., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Bayer AG, Johnson & Johnson.

Key Takeaways for Decision-Makers

  • Precision medicine, including PCSK9 inhibitors and RNA therapeutics, is reshaping lipid-lowering strategies and patient management protocols in cardiovascular care.
  • Integration of digital health solutions increases adherence and enables real-time monitoring, supporting optimized clinical outcomes and evidence-based payer negotiations.
  • Regulatory agencies are piloting accelerated approvals and value-based reimbursement models, prompting the formation of data-driven partnerships across the healthcare value chain.
  • Regional dynamics determine adoption rates, with mature healthcare systems favoring next-generation therapies and emerging markets focusing on broadening access and infrastructure development.
  • Collaborative industry models, including partnerships with academic centers and technology firms, are fast-tracking innovation and market entry.
  • Strategic diversification of supply chains and localized production is gaining importance due to evolving trade environments and risk mitigation needs.

Tariff Impact: Navigating the 2025 U.S. Policy Environment

The implementation of updated United States tariffs in 2025 has introduced supply chain challenges for atherosclerosis drug manufacturers. Increased duties on imported pharmaceutical ingredients are influencing procurement strategies and driving a closer evaluation of domestic and regional manufacturing capabilities. While these changes aim to bolster local resilience, they also add complexity to global partnerships and can affect pricing negotiations. Market participants are proactively exploring alternative agreements and regional alliances to protect continuity and control costs in a volatile trade and regulatory environment.

Methodology & Data Sources

Findings are grounded in a robust methodology blending secondary research from peer-reviewed journals, industry white papers, and regulatory filings, with primary insights obtained through expert interviews. Advanced statistical modeling and data triangulation ensure accuracy and relevance, and all underlying assumptions are openly documented for transparency.

Why This Report Matters

  • Enables executives to benchmark growth opportunities by drug class, region, and end user category, with actionable insights for market positioning.
  • Delivers strategic intelligence on regulatory and supply chain risk mitigation for informed investment and partnership decision-making.
  • Facilitates competitive analysis for sustained innovation and operational excellence in the evolving atherosclerosis treatment landscape.

Conclusion

In summary, the atherosclerosis drugs market is shaped by technology-driven therapies, adaptive regulation, and strategic collaboration. Stakeholders equipped with granular insights and agile strategies will be positioned to drive meaningful advancements in cardiovascular health and sustained market success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of PCSK9 inhibitors on competitive pricing and market expansion in atherosclerosis treatment
5.2. Clinical progress of siRNA therapies targeting lipoprotein(a) reduction in atherosclerosis management
5.3. Expansion of combination regimens with bempedoic acid and statins to enhance patient adherence and outcomes
5.4. Emergence of oral PCSK9 inhibitors as a disruptive alternative to injectable biologics in atherosclerosis care
5.5. Adoption of genetic profiling and personalized medicine strategies to tailor atherosclerosis drug therapies to individual patients
5.6. Integration of digital health platforms and remote monitoring to improve adherence in atherosclerosis pharmacotherapy programs
5.7. Impact of biosimilar monoclonal antibody entries on affordability and access to atherosclerosis biologic therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Atherosclerosis Drugs Market, by Drug Class
8.1. Introduction
8.2. Bile Acid Sequestrants
8.2.1. Cholestyramine
8.2.2. Colesevelam
8.2.3. Colestipol
8.3. Fibrates
8.3.1. Fenofibrate
8.3.2. Gemfibrozil
8.4. Niacin
8.4.1. Extended Release
8.4.2. Immediate Release
8.5. Omega-3 Fatty Acids
8.5.1. Docosahexaenoic Acid
8.5.2. Eicosapentaenoic Acid
8.6. PCSK9 Inhibitors
8.6.1. Alirocumab
8.6.2. Evolocumab
8.7. Statins
8.7.1. Atorvastatin
8.7.2. Pravastatin
8.7.3. Rosuvastatin
8.7.4. Simvastatin
9. Atherosclerosis Drugs Market, by Administration Route
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.3. Oral
9.3.1. Capsule
9.3.2. Tablet
10. Atherosclerosis Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Atherosclerosis Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.3. Injection
11.4. Tablet
12. Atherosclerosis Drugs Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Home Care
12.4. Hospital
13. Americas Atherosclerosis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Atherosclerosis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Atherosclerosis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Novartis AG
16.3.3. Pfizer Inc.
16.3.4. Sanofi S.A.
16.3.5. AstraZeneca PLC
16.3.6. Regeneron Pharmaceuticals, Inc.
16.3.7. Merck & Co., Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. Bayer AG
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ATHEROSCLEROSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ATHEROSCLEROSIS DRUGS MARKET: RESEARCHAI
FIGURE 26. ATHEROSCLEROSIS DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ATHEROSCLEROSIS DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ATHEROSCLEROSIS DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 161. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 164. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 165. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 166. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 167. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 168. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 169. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 170. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 171. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 172. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 173. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 174. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 175. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 176. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 177. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 178. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 179. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 180. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 181. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 190. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 191. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 192. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 193. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 194. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 195. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 196. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 197. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 198. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 211. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 320. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 321. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2024 (USD MILLION)
TABLE 322. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2025-2030 (USD MILLION)
TABLE 323. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2024 (USD MILLION)
TABLE 324. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2025-2030 (USD MILLION)
TABLE 325. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2024 (USD MILLION)
TABLE 326. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2025-2030 (USD MILLION)
TABLE 327. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2024 (USD MILLION)
TABLE 328. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2025-2030 (USD MILLION)
TABLE 329. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 330. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2025-2030 (USD MILLI

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Atherosclerosis Drugs market report include:
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Regeneron Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 25.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.25 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Atherosclerosis Drugs Market Report 2025 - Product Image

Atherosclerosis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Atherosclerosis Drugs - Global Strategic Business Report - Product Image

Atherosclerosis Drugs - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From
Atherosclerosis Therapeutics - Global Strategic Business Report - Product Image

Atherosclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 - Product Image

Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.